Diligence memo · auto-generated · as of July 3, 2026
Jupiter Orphan Therapeutics, Inc.
Jupiter Orphan Therapeutics, Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Jupiter Orphan Therapeutics, Inc. operates in Pharma, based in JUPITER.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Jupiter Orphan Therapeutics, Inc. has raised $1.4M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $1.0M on 2016-12-19.
Most recent recorded round closed around 2017-11-17.
Valuation (modeled)modeled
Provath models Jupiter Orphan Therapeutics, Inc. at approximately $3.8M (range $76K–$30M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.06× the median modeled value of Seed Pharma companies in 2016–2018 (6 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 8 months.
Last raise 8.6 yr ago; this sector typically re-raises about every 16 months.
Silent for over 3× the sector's normal cadence.
The last round was 10.0× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 39% of Pharma peers (310 compared).
Modeled value ranks above 25% of those peers.
Closest niche peers: Capstone Therapeutics Corp., Luma Therapeutics, Inc., Eliaz Therapeutics, Inc., Oncology Honduras, LLC, Eikonizo Therapeutics, Inc..
Peoplefiled
5 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.